XML 73 R62.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and contingencies - Narrative (Details) - USD ($) $ in Millions |  |  | 1 Months Ended | 9 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 29, 2020 | Apr. 29, 2020 | Aug. 31, 2021 | Dec. 31, 2019 | May 31, 2019 | Sep. 30, 2021 | Dec. 31, 2019 | May 29, 2020 | Apr. 20, 2017 | Jun. 30, 2016
Akcea |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Upfront licensing fee |  |  |  |  |  | $ 12.0 |  |  |  |
Milestone payments |  |  | $ 4.0 |  |  |  |  |  |  |
Akcea | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 4.0 |  |  |  |
Censa |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Asset acquisition, development and regulatory milestones |  |  |  |  |  |  |  | $ 109.0 |  |
Asset acquisition, initial milestone |  |  |  |  |  |  |  | 30.0 |  |
Censa | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Asset acquisition, milestone, amount |  |  |  |  |  |  |  | 217.5 |  |
Asset acquisition, net sales milestone |  |  |  |  |  |  |  | $ 160.0 |  |
Agilis Merger Agreement | Marathon Pharmaceuticals, LLC |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  |  |  |  | $ 50.0 |
Agilis Merger Agreement | Akcea |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  | $ 4.0 | $ 6.0 | 4.0 | $ 6.0 |  |  |
SMA License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Potential royalty payments due on net product sales |  |  |  |  |  | 52.5 |  |  |  |
Agilis |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | 40.0 |  |  |  |
Development milestone obligation payments made |  |  |  |  |  | $ 2.4 |  |  |  |
Agilis | Minimum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Product sales (as a percent) |  | 2.00% |  |  |  | 2.00% |  |  |  |
Agilis | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | $ 60.0 |  |  |  |
Priority review voucher amount |  |  |  |  |  | 535.0 |  |  |  |
Net sales amount |  |  |  |  |  | $ 150.0 |  |  |  |
Product sales (as a percent) |  | 6.00% |  |  |  | 6.00% |  |  |  |
Development milestone payment obligations, net of cancellation and forfeiture |  |  |  |  |  | $ 20.0 |  |  |  |
Agilis | Rights Exchange Agreement |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Contingent liability cancellation and forfeiture of potential milestone payments |  |  |  |  |  | 174.0 |  |  |  |
Development milestone payment obligations, cancellation and forfeiture |  |  |  |  |  | 37.6 |  |  |  |
Contingent liability, cancellation and forfeiture | $ 211.6 |  |  |  |  |  |  |  |  |
Agilis | Rights Exchange Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture |  | $ 361.0 |  |  |  |  |  |  |  |
BioElectron | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | 200.0 |  |  |  |
Net product revenue | Wellcome Trust |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  |  |  |  |  | $ 0.8
Net product revenue | Wellcome Trust | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | $ 22.4 |  |  |  |

X
- Definition Asset Acquisition, Development And Regulatory Milestones + References No definition available. + Details
Name: | ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Initial Milestone + References No definition available. + Details
Name: | ptct_AssetAcquisitionInitialMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Milestone, Amount + References No definition available. + Details
Name: | ptct_AssetAcquisitionMilestoneAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Net Sales Milestone + References No definition available. + Details
Name: | ptct_AssetAcquisitionNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix: | ptct_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of development milestone obligation payments made during the period. + References No definition available. + Details
Name: | ptct_DevelopmentMilestoneObligationPaymentsMade
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development Milestone Payment Obligations, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development Milestone Payment Obligations, net of cancellation and forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment which the entity is obliged to pay upon regulatory approval + References No definition available. + Details
Name: | ptct_MilestonePotentialAchievementsRegulatoryApproval
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement. + References No definition available. + Details
Name: | ptct_PotentialRoyaltiesDueNetProductSales
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront Licensing Fee + References No definition available. + Details
Name: | ptct_UpfrontLicensingFee
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherCommitmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_AkceaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_CensaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |